S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.26 (+1.23%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   398.85 (+5.42%)
NIO   7.59 (+0.80%)
BABA   83.74 (+5.27%)
AMD   120.31 (+1.78%)
T   15.80 (+0.45%)
F   12.12 (+1.00%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.61%)
GE   104.97 (+3.39%)
DIS   88.62 (+0.75%)
AMC   4.61 (+2.44%)
PFE   38.02 (+0.00%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.26 (+1.23%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   398.85 (+5.42%)
NIO   7.59 (+0.80%)
BABA   83.74 (+5.27%)
AMD   120.31 (+1.78%)
T   15.80 (+0.45%)
F   12.12 (+1.00%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.61%)
GE   104.97 (+3.39%)
DIS   88.62 (+0.75%)
AMC   4.61 (+2.44%)
PFE   38.02 (+0.00%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.26 (+1.23%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   398.85 (+5.42%)
NIO   7.59 (+0.80%)
BABA   83.74 (+5.27%)
AMD   120.31 (+1.78%)
T   15.80 (+0.45%)
F   12.12 (+1.00%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.61%)
GE   104.97 (+3.39%)
DIS   88.62 (+0.75%)
AMC   4.61 (+2.44%)
PFE   38.02 (+0.00%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.26 (+1.23%)
AAPL   179.98 (+1.54%)
MSFT   331.96 (+1.09%)
META   273.40 (+3.28%)
GOOGL   123.48 (+0.50%)
AMZN   123.28 (+2.24%)
TSLA   208.38 (+2.18%)
NVDA   398.85 (+5.42%)
NIO   7.59 (+0.80%)
BABA   83.74 (+5.27%)
AMD   120.31 (+1.78%)
T   15.80 (+0.45%)
F   12.12 (+1.00%)
MU   69.24 (+1.52%)
CGC   0.83 (-0.61%)
GE   104.97 (+3.39%)
DIS   88.62 (+0.75%)
AMC   4.61 (+2.44%)
PFE   38.02 (+0.00%)
PYPL   63.16 (+1.89%)
NFLX   404.18 (+2.26%)
NASDAQ:TWST

Twist Bioscience (TWST) Stock Forecast, Price & News

$16.16
+1.01 (+6.67%)
(As of 02:35 PM ET)
Compare
Today's Range
$14.75
$16.27
50-Day Range
$11.49
$16.28
52-Week Range
$11.46
$58.76
Volume
580,013 shs
Average Volume
1.32 million shs
Market Capitalization
$923.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.17

Twist Bioscience MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
63.2% Upside
$26.17 Price Target
Short Interest
Bearish
24.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.74mentions of Twist Bioscience in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$132,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.96) to ($3.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

821st out of 1,980 stocks

Biological Products, Except Diagnostic Industry

111th out of 330 stocks


TWST stock logo

About Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Stock News Headlines

Twist Bioscience (NASDAQ:TWST) Stock Price Up 6.2%
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
Twist Bioscience (NASDAQ:TWST) Stock Price Down 8.6%
Twist Bioscience (NASDAQ:TWST) Trading Up 5.1%
Reconsidering Twist Biosciences
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Analyst Ratings for Twist Bioscience
Earnings Preview: Twist Bioscience
Twist Bioscience (NASDAQ:TWST) Sets New 52-Week Low at $12.96
See More Headlines

TWST Price History

TWST Company Calendar

Last Earnings
5/05/2023
Today
6/01/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TWST
Fax
N/A
Employees
652
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.17
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+70.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-217,860,000.00
Pretax Margin
-92.92%

Debt

Sales & Book Value

Annual Sales
$203.57 million
Book Value
$12.32 per share

Miscellaneous

Free Float
50,404,000
Market Cap
$878.97 million
Optionable
Not Optionable
Beta
1.17

Key Executives

  • Emily Marine LeproustEmily Marine Leproust
    Chairman & Chief Executive Officer
  • Patrick J. FinnPatrick J. Finn
    President & Chief Operating Officer
  • James M. ThorburnJames M. Thorburn
    Chief Financial Officer
  • Siyuan Chen
    Chief Technology Officer
  • Nimisha Srivastava
    Senior Vice President-Research & Development













TWST Stock - Frequently Asked Questions

Should I buy or sell Twist Bioscience stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TWST shares.
View TWST analyst ratings
or view top-rated stocks.

What is Twist Bioscience's stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price targets for Twist Bioscience's stock. Their TWST share price forecasts range from $18.00 to $36.00. On average, they anticipate the company's stock price to reach $26.17 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price.
View analysts price targets for TWST
or view top-rated stocks among Wall Street analysts.

How have TWST shares performed in 2023?

Twist Bioscience's stock was trading at $23.81 at the beginning of 2023. Since then, TWST shares have decreased by 35.4% and is now trading at $15.38.
View the best growth stocks for 2023 here
.

When is Twist Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our TWST earnings forecast
.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) announced its earnings results on Friday, May, 5th. The company reported ($1.06) EPS for the quarter, beating analysts' consensus estimates of ($1.09) by $0.03. The business had revenue of $60.18 million for the quarter, compared to analysts' expectations of $56.61 million. Twist Bioscience had a negative net margin of 93.32% and a negative trailing twelve-month return on equity of 27.95%.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its FY 2023 earnings guidance on Sunday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.00 million-$238.00 million, compared to the consensus revenue estimate of $264.18 million.

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.63%), BlackRock Inc. (10.93%), State Street Corp (9.23%), JPMorgan Chase & Co. (7.10%), Sumitomo Mitsui Trust Holdings Inc. (5.98%) and Nikko Asset Management Americas Inc. (5.98%). Insiders that own company stock include Dennis Cho, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends
.

How do I buy shares of Twist Bioscience?

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $15.38.

How much money does Twist Bioscience make?

Twist Bioscience (NASDAQ:TWST) has a market capitalization of $878.97 million and generates $203.57 million in revenue each year. The company earns $-217,860,000.00 in net income (profit) each year or ($3.77) on an earnings per share basis.

How many employees does Twist Bioscience have?

The company employs 652 workers across the globe.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.

This page (NASDAQ:TWST) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -